Business Wire

JPMorganChase to Expand Paris Office Space

Share

JPMorganChase today announces that it has signed a lease on a new building in Paris at 37 Place du Marché Saint-Honoré as the firm has passed over 1,000 employees in the city. The new office is situated behind the bank’s headquarters at 14 Place Vendôme, and is opposite 21 Place du Marché Saint-Honoré, where the bank also has employees. While this investment will see the firm reduce the buildings it occupies in central Paris from six to just three, overall office space will increase significantly, creating a much better working environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515443526/en/

The new building will open in early 2027 after a complete refurbishment, at which point all surplus buildings will be exited. Many employees will relocate to the new building to free up space in 14 Place Vendôme in particular, and to improve client facilities.

Jamie Dimon, CEO of JPMorganChase said: “This new investment reflects the runaway success we have made of our business in Paris over the last five years in particular. Even beyond our expectations, we have continued to attract some of our best people to the city and we have hired more people locally too. Between this new building, and our historic home at 14 Place Vendôme, we will be ready for the next generation of bankers.”

Designed by prominent architect, Ricardo Bofill, the 16,000 square-metre building will create a flexible and collaborative workplace, providing a world-class experience for employees with large open floors and modern amenities across five storeys.

President Emmanuel Macron, said: “Our strategy to make Paris the most attractive location in the EU for financial services companies continues to pay off. JPMorganChase has had a long term presence and relationship with the Republic of France, and has been a model corporate citizen as it has expanded in recent years, investing in our local communities in Paris as it has done so.”

This announcement coincides with the 20th anniversary of the firm’s flagship Global Markets Conference, which brings together companies and investors in Paris each year, underscoring the importance of Paris as a financial centre. When it is ready, the bank’s Sales & Trading team will be among the first to move into the new building at 37 Place du Marché Saint-Honoré.

Modern workplace prioritising employee well-being

37 Place du Marché Saint-Honoré will be designed to adapt to the future of work and will feature a mix of formal and informal meeting spaces to encourage innovative thinking and collaboration. It will also house a café space for employees to gather and socialise.

Employees also have access to best-in-class wellness experiences. From natural lighting to the use of air quality sensors and biophilic design, 37 Place du Marché Saint-Honoré will support employees’ physical and emotional well-being. And with facilities including nursing and meditation rooms, terraces and roof-tops to provide much-coveted private outdoor space in central Paris, there will be plenty of opportunity to achieve balance in the working day.

In line with JPMorganChase’s global sustainability commitments across its real estate portfolio, the aim is for the building to achieve advanced environmental and wellness certifications including: BREEM (Excellent), Well Core & Shell (Gold), Wiredscore (Platinum), and SmartScore (Silver).

The refurbishment is already underway under the management of CBRE Investment Management, which is looking to set a new benchmark for sustainable, intelligent and high-performance offices in the city.

Serving Paris and France

For more than 150 years, JPMorganChase has served its clients and local communities in Greater Paris in good and tough times — from helping citizens take part in the country’s economic growth to supporting the Allies during World War I. Today, as one of the longest operating American banks in France and a significant employer, we remain committed to that mission, strengthening local communities by lifting up individuals as well as institutions, including small, medium, and large companies, schools and healthcare facilities.

Since 2018 when it announced major philanthropic partnerships in Seine-Saint-Denis, the bank has invested $100 million in the region through local partnerships. Most recently, this included the creation of Bpifrance Spark Fund, an investment initiative together with Bpifrance, aimed at providing capital to gender diverse private investment firms and funds investing in strategies that are positively impacting society and communities.

With more than 1,000 employees in France, the bank offers services in commercial and investment banking, sales & trading, private banking and asset management. It has 1,000 employees in Paris who come from 61 different countries, and so it benefits from a true melting pot of global ideas.

About JPMorganChase

JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America (“U.S.”), with operations worldwide. JPMorganChase had $4.4 trillion in assets and $351 billion in stockholders’ equity as of March 31, 2025. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. Under the J.P. Morgan and Chase brands, the Firm serves millions of customers in the U.S., and many of the world’s most prominent corporate, institutional and government clients globally. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250515443526/en/

Contacts

Media Contacts:
Anne Roppé
+33 1 40 15 47 71
anne.roppe@jpmorgan.com

Patrick Burton
+44 20 7134 9041
patrick.o.burton@jpmorgan.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aptiv and Vecna Robotics to Develop Next Generation Autonomous Mobile Robots18.12.2025 14:00:00 CET | Press Release

Aptiv PLC (NYSE: APTV), a global industrial technology leader, and Vecna Robotics, a pioneer in AI-driven autonomous material handling solutions, today announced a strategic collaboration to co-develop next-generation Autonomous Mobile Robot (AMR) solutions designed to deliver cost-efficient automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218958100/en/ Aptiv’s advanced perception portfolio and machine learning technologies will be integrated into Vecna Robotics’ platform. This partnership combines Aptiv’s industry-leading portfolio, with Vecna Robotics’ advanced autonomy and orchestration platform to provide safer, more efficient, and scalable material handling systems. “Automation is transforming the way goods move through warehouses and factories, with devices that sense, think and act in real time,” said Javed Khan, Executive Vice President, Intelligent Systems, Aptiv. “Our collaboration with Vecna Robotics

Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions18.12.2025 14:00:00 CET | Press Release

Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health, today announced its launch with a $165 million financing. The Series A, co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet will support the advancement of Syremis’ pipeline through clinical proof of concept. Schizophrenia and other psychotic disorders remain among the most debilitating and underserved conditions worldwide, with more than 20 million people affected and facing considerable disability, elevated relapse rates, and reduced life expectancy. Despite decades of need, current treatments often fall short in both efficacy and tolerability. Syremis’ lead program, ST-905, is a dual M1/M4 muscarinic agonist under development for schizophrenia and other neuropsychiatric conditions and is currently in Phase 1. The molecule’s differentiated potency

Cinemo at CES 2026: Hyper-Personalized Experiences in the Car and Beyond18.12.2025 13:55:00 CET | Press Release

Cinemo, a global leader and highly innovative one-stop-shop provider for fully integrated digital media products is presenting its newest innovations in exclusive live demos at CES 2026 in Las Vegas, from January 6-9. Cinemo will present a range of in-car experiences that bring intelligence, hyper-personalization, and entertainment to every moment - elevating every ride into a unique experience for drivers and passengers. From collaborative trip planning to effortless onboarding, every feature is crafted to enable fascinating experiences with the right content at the right time for the right audience - for the perfect ride. Passengers can enjoy personalized media recommendations, immersive gaming, and a consistent, intuitive experience across every seat, screen, and journey. This will mark Cinemo’s first time presenting these demo showcases live of breakthrough solutions that redefine the future of in-vehicle intelligence. Cinemo is bringing agentic AI into the vehicle and is extending

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press Release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye